Few menopause treatments have been as misunderstood as vaginal estrogen. Much of the worry traces back to research on a very different product, and the science has moved considerably. Here is a clear look at what the evidence shows today.
Where the fear came from
For years, vaginal estrogen products carried a prominent 'black box' warning from the FDA, the agency's most serious safety alert, describing risks such as heart disease, breast cancer, and dementia. Those warnings were largely extrapolated from the Women's Health Initiative, a large study of systemic hormone therapy that used a higher-dose oral product. Applying those findings to low-dose local estrogen was, in the view of many specialists, a mismatch.
What absorption studies show
The defining feature of local vaginal estrogen is how little reaches the bloodstream. As noted in The Menopause Society's 2020 position statement, blood estradiol after two weeks of daily 10 mcg insert use was about 4.6 pg/mL, statistically indistinguishable from the level in women taking a placebo, meaning women using no active treatment at all. That low systemic exposure is the foundation of its favorable safety profile.
The breast cancer question
This is the concern we hear most. A 2024 study in JAMA Oncology by McVicker and colleagues examined vaginal estrogen use and survival among 49,237 women with breast cancer across two national cohorts in Scotland and Wales, and did not find evidence of worse survival associated with its use. A separate large cohort analysis found similar breast cancer recurrence rates between users and non-users of vaginal estrogen. The evidence is more nuanced for women taking aromatase inhibitors, a class of medication that lowers estrogen throughout the body and is widely used to treat hormone-receptor-positive breast cancer. Because these drugs work by driving estrogen levels very low, there is a theoretical concern that even the small amount absorbed from vaginal estrogen could work against them, which is exactly why anyone with a history of breast cancer should make this decision together with their oncologist.
A major shift in 2025
In November 2025, the FDA announced it would remove the boxed warnings related to cardiovascular disease, breast cancer, and dementia from menopausal hormone therapy products, including low-dose vaginal estrogen. The Menopause Society, the leading North American professional body of clinicians and researchers who specialize in menopause (formerly the North American Menopause Society), supported the change for local vaginal estrogen, describing it as a safe and effective therapy for a condition that affects most menopausal women. Because the Society sets much of the clinical guidance that menopause providers follow, its backing carries real weight.
What to expect, and when to check in
Side effects, when they occur, are usually mild and local, such as temporary irritation or discharge. Anyone with unexplained vaginal bleeding should be evaluated, and women with a history of estrogen-sensitive cancer should consult their oncologist before starting.
One point that applies to every woman, whether or not she uses vaginal estrogen: convenient online care is a good way to start treatment, but it does not replace regular in-person pelvic and gynecologic examinations. Routine exams and age-appropriate screening remain an essential part of your care, and some symptoms genuinely need a physical exam to diagnose correctly.
Related reading
Sources
- McVicker L, et al. Vaginal Estrogen Therapy Use and Survival in Females With Breast Cancer. JAMA Oncol. 2024;10(1):103-108.
- The Menopause Society. Statement on the FDA hormone therapy announcement, November 2025.
- U.S. FDA / HHS. Removal of boxed warnings from menopausal hormone therapies, November 10, 2025.
- The Menopause Society (NAMS). 2020 Genitourinary Syndrome of Menopause Position Statement. Menopause. 2020;27(9):976-992.
This article is for educational purposes and is not a substitute for personalized medical advice.